First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Stock Information for Adaptimmune Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adaptimmune Therapeutics plc

Adaptimmune Reports Q2 Financial Results and Provides Business Update
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.